PMID- 33144857
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1687-8450 (Print)
IS  - 1687-8469 (Electronic)
IS  - 1687-8450 (Linking)
VI  - 2020
DP  - 2020
TI  - HER2 Heterogeneity in Gastric Cancer: A Comparative Study, Using Two Commercial 
      Antibodies.
PG  - 8860174
LID - 10.1155/2020/8860174 [doi]
LID - 8860174
AB  - BACKGROUND: Although amplification of the gene encoding human epidermal growth 
      factor receptor 2 (HER2) is used as an indicator for response to trastuzumab, the 
      reported response rate is low, and few patients with gastric cancer (GC) benefit 
      from this individualized therapy. The aim of this study was to examine the 
      expression of c-erbB-2 oncoprotein (HER2), in GC samples, using two commercial 
      immunohistochemical (IHC) antibodies, and to validate the results by checking 
      HER2 gene amplification by fluorescence in situ hybridization (FISH). METHODS: We 
      assessed the IHC expression of HER2 using the polyclonal antibody from Dako and 
      CB11 clone from Leica, in 93 consecutive cases of GC samples. In all of the 
      cases, FISH analysis was also performed using the BOND-MAX platform. RESULTS: No 
      significant difference was observed between the two HER2 antibodies. Of the 93 
      cases, 22.58% demonstrated at least focal and 1+ HER2 positivity. Seven cases 
      (7.53%) exhibited 3+ expression, and another 7 carcinomas (7.53%) were equivocal 
      (2+). HER2 amplification was seen in 11 cases (11.83%), 10 of which were 
      differentiated adenocarcinomas. In 5 of the cases, 2-5 sections were examined, 
      which proved the extremely high intratumorally/intraglandular heterogeneity. FISH 
      heterogeneity was higher in cases with only 2+ positivity on IHC assessment, 
      compared with those showing at least one small focus of 3+ overexpression. HER2 
      amplification proved to be an independent negative prognostic factor. 
      CONCLUSIONS: Due to the highly heterogeneous aspect of GC, at least 3-4 slides 
      should be assessed by IHC, before considering a tumor to be HER2-negative. In 
      cases with small 3+ foci representing less than 5% of tumor and in equivocal (2+) 
      cases, FISH analysis remains the gold standard method.
CI  - Copyright (c) 2020 Catalin Bogdan Satala et al.
FAU - Satala, Catalin Bogdan
AU  - Satala CB
AD  - Department of Pathology, George Emil Palade University of Medicine, Pharmacy, 
      Sciences and Technology, Targu-Mures, Romania.
AD  - Department of Pathology, Clinical County Emergency Hospital, Targu-Mures, 
      Romania.
FAU - Jung, Ioan
AU  - Jung I
AD  - Department of Pathology, George Emil Palade University of Medicine, Pharmacy, 
      Sciences and Technology, Targu-Mures, Romania.
FAU - Stefan-van Staden, Raluca Ioana
AU  - Stefan-van Staden RI
AD  - Laboratory of Electrochemistry and PATLAB, National Institute of Research for 
      Electrochemistry and Condensed Matter, Bucharest, Romania.
FAU - Kovacs, Zsolt
AU  - Kovacs Z
AD  - Department of Pathology, George Emil Palade University of Medicine, Pharmacy, 
      Sciences and Technology, Tirgu-Mures, Romania.
FAU - Molnar, Calin
AU  - Molnar C
AD  - Department of Surgery, George Emil Palade University of Medicine, Pharmacy, 
      Sciences and Technology, Tirgu-Mures, Romania.
AD  - Department of Surgery, Clinical County Emergency Hospital, Targu-Mures, Romania.
FAU - Bara, Tivadar Jr
AU  - Bara T Jr
AD  - Department of Surgery, Clinical County Emergency Hospital, Targu-Mures, Romania.
FAU - Fulop, Zsolt Zoltan
AU  - Fulop ZZ
AD  - Department of Surgery, George Emil Palade University of Medicine, Pharmacy, 
      Sciences and Technology, Tirgu-Mures, Romania.
AD  - Department of Surgery, Clinical County Emergency Hospital, Targu-Mures, Romania.
FAU - Gurzu, Simona
AU  - Gurzu S
AUID- ORCID: 0000-0003-3968-5118
AD  - Department of Pathology, George Emil Palade University of Medicine, Pharmacy, 
      Sciences and Technology, Targu-Mures, Romania.
AD  - Department of Pathology, Clinical County Emergency Hospital, Targu-Mures, 
      Romania.
AD  - Department of Pathology, Research Center (CCAMF), Tirgu-Mures, Romania.
LA  - eng
PT  - Journal Article
DEP - 20201020
PL  - Egypt
TA  - J Oncol
JT  - Journal of oncology
JID - 101496537
PMC - PMC7596543
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2020/11/05 06:00
MHDA- 2020/11/05 06:01
PMCR- 2020/10/20
CRDT- 2020/11/04 05:42
PHST- 2020/08/27 00:00 [received]
PHST- 2020/10/08 00:00 [revised]
PHST- 2020/10/12 00:00 [accepted]
PHST- 2020/11/04 05:42 [entrez]
PHST- 2020/11/05 06:00 [pubmed]
PHST- 2020/11/05 06:01 [medline]
PHST- 2020/10/20 00:00 [pmc-release]
AID - 10.1155/2020/8860174 [doi]
PST - epublish
SO  - J Oncol. 2020 Oct 20;2020:8860174. doi: 10.1155/2020/8860174. eCollection 2020.